Cargando…

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report

There are limited data on the clinical efficiency of afatinib in non‐small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations. Moreover, the efficacy and safety of afatinib in elderly patients with these mutations has not been established. Here, we desc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iida, Yuko, Kumasawa, Fumio, Shimizu, Tetsuo, Shintani, Yoshitaka, Takahashi, Noriaki, Gon, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996987/ https://www.ncbi.nlm.nih.gov/pubmed/31779047 http://dx.doi.org/10.1111/1759-7714.13269

Ejemplares similares

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report
por: Zhang, Yao, et al.
Publicado: (2021)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
por: Lin, Ruiting, et al.
Publicado: (2021)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
por: Shijubou, Naoki, et al.
Publicado: (2021)

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay
por: Kimura, Shinichi, et al.
Publicado: (2018)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
por: Watanabe, Satoshi, et al.
Publicado: (2014)

The Diagnosis of Exogenous Lipoid Pneumonia Caused by the Silent Aspiration of Vegetable Oil Using a Lipidomic Analysis
por: Shimizu, Tetsuo, et al.
Publicado: (2019)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Genomic analysis between idiopathic pulmonary fibrosis and associated lung cancer using laser‐assisted microdissection: A case report
por: Iida, Yuko, et al.
Publicado: (2021)

Comprehensive genetic analysis of histological components of combined small cell carcinoma
por: Iida, Yuko, et al.
Publicado: (2022)

861. Health Disparities in HIV and Pregnancy
por: Abbas, Anum, et al.
Publicado: (2018)

Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report
por: Liu, Qin, et al.
Publicado: (2021)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

EGFR-L861Q突变对TKI类药物敏感性预测分析及病例报道
Publicado: (2015)

Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma
por: Abdelmaksoud-Dammak, Rania, et al.
Publicado: (2022)

Fundus Examination of 23,861 Newborns by Digital Imaging in Ningbo
por: Liu, Delin, et al.
Publicado: (2021)

A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer
por: Shimizu, Tetsuo, et al.
Publicado: (2019)

Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

Afatinib-induced severe esophagitis in a lung cancer patient with an activated epidermal growth factor receptor mutation: A case report
por: Inoue, Takako, et al.
Publicado: (2017)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
por: Nishiya, Naoyuki, et al.
Publicado: (2019)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
por: Yang, Wei, et al.
Publicado: (2023)

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion
por: Ou, Lanzi, et al.
Publicado: (2022)

Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

Retrospective Analysis of the Incidence of Drug-Induced Interstitial Lung Disease by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Survival in Patients Aged 75 Years or Older with Lung Cancer
por: Ishibashi, Masayuki, et al.
Publicado: (2023)

Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil
por: Roscigno, Robert, et al.
Publicado: (2020)

Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience
por: Gürsoy, Pınar, et al.
Publicado: (2022)

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
por: Villaruz, L.C., et al.
Publicado: (2023)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report
por: Taniguchi, Yuri, et al.
Publicado: (2019)

Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex
por: Wu, Jiqin, et al.
Publicado: (2021)

NIPAT as Non-Invasive Prenatal Paternity Testing Using a Panel of 861 SNVs
por: Giannico, Riccardo, et al.
Publicado: (2023)

Effective ferroptotic small-cell lung cancer cell death from SLC7A11 inhibition by sulforaphane
por: Iida, Yuko, et al.
Publicado: (2021)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2017)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022)

Successful treatment of refractory brain metastases from ALK‐positive lung cancer with lorlatinib
por: Nakagawa, Yoshiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k938lspkoamu96k6isnt1r11m1